Skip to content

Ketamine: all studies

Page 79 of 448: studies 781 to 790 of 4,475, newest first. Back to the ketamine overview

Research

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

DOI: 10.1016/j.jad.2025.119632 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonists Posttraumatic Stress Treatment resistant depression +6

Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.

Journal of Eating Disorders June 10, 2025 Camilla Lindvall Dahlgren, Elisabeth Tverrli, Lowan Han Stewart 3 citations

Ketamine, an N-methyl-D-aspartate receptor antagonist, has demonstrated rapid antidepressant effects at sub-anesthetic doses, making it a promising candidate for treatment-resistant mood disorders, anxiety, post-traumatic stress disorder, suicidality, and recently, eating disorders (EDs). However, its effects are transient, and ketamine-assisted psychotherapy (KAP) has emerged as a method to...

DOI: 10.1186/s40337-025-01313-y (opens in new tab) Full text (opens in new tab) Case report Dissociation Follow-up Ketamine-assisted psychotherapy +5

Computational modeling of ketamine-induced changes in gamma-band oscillations: The contribution of parvalbumin and somatostatin interneurons.

PLoS Computational Biology June 9, 2025 Jessie Rademacher, Tineke Grent-'t-Jong, Davide Rivolta et al. 2 citations

Ketamine, an NMDA receptor (NMDA-R) antagonist, produces psychotomimetic effects when administered in sub-anesthetic dosages. While previous research suggests that Ketamine alters the excitation/inhibition (E/I)-balance in cortical microcircuits, the precise neural mechanisms by which Ketamine produces these effects are not well understood. We analyzed resting-state MEG data from n = 12...

DOI: 10.1371/journal.pcbi.1013118 (opens in new tab) Full text (opens in new tab) Psychopharmacology Ketamine research Neural circuits Brain imaging

Selective transcriptomic recovery by ( 2R,6R )-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers

bioRxiv (Cold Spring Harbor Laboratory) June 8, 2025 Anna Onisiforou, Morfeas Koumas, Andria Michael et al. preprint

Abstract Background Opioid abstinence induces persistent emotional disturbances and widespread neuroplastic changes, in areas of the brain including the hippocampus. Although ketamine and its metabolite ( 2R,6R )-hydroxynorketamine (HNK) show potential in reversing opioid abstinence-related deficits in rodents, the molecular mechanisms underlying their efficacy remain poorly understood. Methods...

DOI: 10.1101/2025.06.04.657935 (opens in new tab) Full text (opens in new tab) Transcriptome Μ-opioid receptor Endocrinology Pharmacology +1

Ketamine-Ethanol Combination Decreases Reduced Glutathione Levels and Activates both Intrinsic and Extrinsic Apoptotic Pathways Prior to Neuronal Death in SH-SY5Y Cells.

Neurotoxicity Research June 7, 2025 Felype Valentim Duarte Castelhano, Carolina Aparecida de Faria Almeida, Giulia de Assis Braz et al. 3 citations

Ketamine is an anesthetic drug that has been illegally used due to its hallucinogenic effects. Its use is often concomitant with drugs such as ethanol, which can cause irreversible damage to the central nervous system. This study investigates the neurotoxicity of ketamine-ethanol combination in human neuroblastoma SH-SY5Y cell line, exploring the mechanisms preceding cell death. Cell viability,...

DOI: 10.1007/s12640-025-00751-5 (opens in new tab) Full text (opens in new tab) Ketamine Ethanol Glutathione Neurotoxicity neurotoxic effects +8

Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.

The International Journal of Neuropsychopharmacology June 6, 2025 Benjamin Spurny-Dworak, Thomas Liebe, Samantha Graf et al. 2 citations

The N-methyl-D-aspartate receptor antagonist ketamine has found broad application in the field of psychiatry. Due to its rapid antidepressant and anti-suicidal properties, it is used as a treatment for major depressive disorder. Furthermore, ketamine evokes dissociative and psychotropic states, which allows the modeling of schizophrenic symptoms. The thalamus, a main target for ketamine's...

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Journal of Psychopharmacology June 5, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 19 citations

We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...

Neuroprotective Role of Ketamine in Reducing Neuroinflammation and Enhancing Neuroplasticity Against a Cortisol-Induced In Vitro Stress Model.

Molecular Neurobiology June 5, 2025 Lucas C. Santos, Fernanda Dos Santos Petry, Carolina Saibro-Girardi et al. 4 citations

Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Disorder (MDD) and suicidal behavior, significant hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis is observed, characterized by excessive cortisol release, which in turn stimulates the production of pro-inflammatory mediators....

Decoupling of motor cortex to movement in Parkinson's dyskinesia rescued by sub-anaesthetic ketamine.

Brain June 3, 2025 Abhilasha Vishwanath, Mitchell J Bartlett, Torsten Falk et al. 8 citations

Gamma-band and single-unit neural activity in primary motor cortex are involved in the control of movement. This activity is disrupted in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), a debilitating consequence of dopamine replacement therapy for PD. Physiological features of LID include pathological narrowband gamma oscillations, finely tuned gamma and altered primary motor...

DOI: 10.1093/brain/awae386 (opens in new tab) Full text (opens in new tab) In vivo electrophysiology 6-hydroxydopamine hemi-lesioned model Cell types Inertial speed +4

Modulation of ER Stress and Inflammation by S-Ketamine, R-Ketamine, and Their Metabolites in Human Microglial Cells: Insights into Novel Targets for Depression Therapy.

Cells June 3, 2025 Marta Jóźwiak-Bębenista, Anna Wiktorowska-Owczarek, Małgorzata Siatkowska et al. 4 citations

Despite affecting millions worldwide, major depressive disorder (MDD) remains a therapeutic challenge, with approximately one-third of patients failing to respond to standard treatments. The need for innovative, molecularly driven therapies has turned attention to ketamine and its enantiomers. While S-ketamine is clinically approved for treatment-resistant depression (TRD), it has various...